By otakuyassine3@gmail.com 
Silverlake Wealth Management LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 10.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,414 shares of the medical research company’s stock after selling 495 shares during the quarter. Silverlake Wealth Management LLC’s holdings in Amgen were worth $1,151,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP bought a new stake in Amgen during the third quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen during the third quarter worth approximately $29,000. Matrix Trust Co bought a new stake in Amgen during the third quarter worth approximately $36,000. Heck Capital Advisors LLC bought a new stake in Amgen during the fourth quarter worth approximately $36,000. Finally, Livelsberger Financial Advisory bought a new stake in Amgen during the third quarter worth approximately $56,000. 76.50% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Wolfe Research assumed coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. TD Cowen upped their target price on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Bank of America reaffirmed an “underperform” rating and set a $256.00 target price on shares of Amgen in a research note on Tuesday, December 10th. Finally, Citigroup cut their target price on Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $314.00.
Check Out Our Latest Stock Analysis on AMGN
Amgen Price Performance
NASDAQ AMGN opened at $289.02 on Wednesday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock’s fifty day moving average price is $270.95 and its 200 day moving average price is $303.82. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market cap of $155.36 billion, a price-to-earnings ratio of 37.01, a PEG ratio of 2.87 and a beta of 0.56.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. As a group, equities research analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current year.
Amgen Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.29%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is currently 115.24%.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.